I have posted about the CGRP blocking medication research in the past:
“CGRP targeted treatment is the first migraine preventative for migraines ever. Ever. The research suggests targeting calcitonin gene-related peptide (CGRP), a protein that helps with triggering, sending, and heightening sensitivity to the migraine pain, can help improve migraine intensity and frequency in migraineurs when blocked. CGRP is released during a migraine. It is a strong vasodilator of cerebral arteries. The serum CGRP levels are elevated in migraine and persistently in chronic migraines. CGRP basically binds to receptors that activate and cause symptoms of migraines like vasodilation, inflammation and pain. If you were to be given an infusion of it, it would trigger a migraine attack. Therefore, the idea is for anti-CGRP and anti-CGRP receptor monoclonal antibodies to help prevent the migraine attacks from happening. It is ‘”the best validated target for migraine, ever,’ says David Dodick, a neurologist at the Mayo Clinic in Phoenix. It may also help finally solve the centuries-old puzzle of what triggers the complex events of a migraine attack, which can cause brain activity to be ‘completely disregulated’ for several days, similar to epilepsy and other recurrent, seizurelike disorders, says Michel Ferrari, a neurologist at Leiden University in the Netherlands.’ (Science mag) They are well-tolerated medications without the 801 side effects we tend to see in preventatives now.”
Aimovig is the first to the finish line and is now on the market
I am happy to announce it is now available in Canada!
Aimovig (erenumab) was approved for the treatment of patients with migraine by:
Food and Drug Administration (FDA), USA, on May 17, 20181
- Therapeutic Goods Administration (TGA), Australia, July 2, 20184
- Swissmedic, Switzerland, July 16, 20186
- European Medical Agency (EMA), European Union, July 30, 20185
- Health Canada, Canada, August 1, 20187. Source
- It is a once a month CGRP blocking medication. (How to take)
- About 50% of responders get a 50% reduction in migraines.
- And it can be taken with Botox from what I have heard from others. Which would even improve results.
- What is mind-blowing is that in one study of chronic migraine 40% had a 50% reduction. We are notoriously difficult to treat and frankly I was quite astonished by this research
This medication is particularly exciting to me given I am chronic and daily. I am a non-responder to preventatives. And only get some intensity reduction and the very occasional free migraine day from Botox. I’ll take that migraine intensity reduction, by the way. I forgot to schedule my last dose of Botox (because of the cognitive issues with vertigo lately) and the migraines have been insanely intense as a result. So the response rate for this well-tolerated medication is impressive. I have heard numerous results from people since it has been approved in the U.S that are exceptional.
In about 3% of people the side effects are:
- injection site irritation
As you might know, with current migraine preventatives such as blood pressure meds, antidepressants, and anti-seizure medications the list of side effects is massive. Topamax, the one most recommended for chronic migraine, is often complained about due to its cognitive issues but, honestly, it has a lot of side effects. Some people cannot tolerate it at all. I had a problem with it and when they increased my dosage I got quite ill. So a preventative designed specifically for migraine that Also doesn’t have a boatload of side effects is extremely promising.